● Compass employees in its Business and Industry division in the United Kingdom will take part in the ilumen™ well-being pilot commencing in July.

● ilumen™ will provide participants with access to a mobile and web application for early screening of mental health symptoms.

● A second UK-based program is proposed within Compass’ Offshore and Remote Division.

● The Compass Group PLC (Compass Group), is the world’s leading food service provider which employs or engages 600,000 people and generates annual revenues of £23.2Billion.

● This agreement aligns with the commercialisation strategy for ilumenTM that the Company has previously communicated to the market.

Melbourne, Australia and Minneapolis, MN – 1 July 2019: Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF), a health technology company announces that it has signed a commercial agreement with Compass Group PLC to begin the first of two programs of its corporate health product, ilumen™.

Compass Group PLC, is a British multinational and the world’s leading food service company with annual revenues of £23.2 billion. It operates in around 45 countries and employs and engages c.600,000 people worldwide. Compass provides support services across the core sectors of Defense, Offshore & Remote; Business & Industry; Healthcare & Seniors; Education and Sports & Leisure.

“Our partnership with Medibio demonstrates our commitment to supporting the mental wellbeing of our workforce and and that of our customers. We are excited to offer employees access to ilumenTM through these initial programs in the United Kingdom and look forward to the possibility of additional programs in the near future,” said Federico Tonetti, Group Safety and Sustainability Director.

As part of the Health & Well-being element of its global ‘Purpose’ strategy, Compass Group implements various programs to support and improve the mental well-being and physical health of its workforce and its clients’ workforce. ilumen™ fits into this strategy by providing participants with early screening for symptoms of depression, anxiety, and stress. The ilumen™ biometric data and subjective assessments provides users with a ‘well-being snapshot’ that they use to monitor and make improvements over time; whilst also providing Compass management with de-identified aggregate data to better support and manage the mental well-being of their workforce.

“Compass Group’s approach to mental well-being is very progressive and needed in today’s corporate wellness environment,” said Jennifer Solitario, Sr. VP, Corporate Health. “We are pleased to partner with Compass Group in their efforts to support both their employees and ultimately that of their client’s in improving mental well-being. “ As Compass Group is a global leader, this agreement aligns with the large scale commercialisation objectives for ilumenTM the Company previously communicated to the market.

– ENDS –

About Medibio LimitedMedibio (ASX: MEB) (OTCQB: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. The company was founded in Australia, with offices now located in Melbourne (Vic),  and Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

Medibio Media Inquiries:
Kristi Hamilton
Director, Strategic Communications
T: +1 952 232 0934

Investor Enquiries:
Peter Taylor
NWR Communications
T: +61 (0) 412 036 231